Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
FDA approval of first muscle-targeted SMA treatment drives high biotech catalyst score.
What changed
FDA approval of first muscle-targeted SMA treatment drives high biotech catalyst score.
Why it matters
FDA approval of first muscle-targeted SMA treatment drives high biotech catalyst score. — impact context not separately stored; see What changed.
← Dashboard
Sep 12, 2026 05:29 PM ET